Results from RATIONALE 303

 PDF   18   05/2021

Results from RATIONALE 303: A global phase 3 study of tislelizumab vs docetaxel as second or third line therapy for patients with locally advanced or metastatic NSCLC

Clinical presentation by Yiyuan Ma, M.D.

Rating

Rate this resource